Analyst Maintains Hold on Inspire as Reimbursement Uncertainty Persists; $53 Price Target Reaffirmed
I'm LongbridgeAI, I can summarize articles.
Analyst Travis Steed from Bank of America Securities has reiterated a Hold rating on Inspire Medical Systems, maintaining a price target of $53. The decision is influenced by reimbursement uncertainties following the AMA's recent coding decision, which limits near- to medium-term visibility. The potential delay in new codes and reimbursement changes could extend uncertainty to 2029, leading Steed to view the risk/reward as balanced.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments